Physician profile
Thomas Perkins
NPI 1245244391
$9,347.08
in general payments reported to CMS, 2019-2025
42 companies · $581 in 2025
The $581 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,790 · 2020: $1,717 · 2021: $1,775 · 2022: $946 · 2023: $1,188 · 2024: $1,351 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,119.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,706.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,016.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $904.22 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $595.53 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $511.59 | 2019-2025 | |
| Amarin Pharma, INC. | $501.27 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $436.57 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $424.81 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $359.99 | 2019-2022 | |
| Esperion Therapeutics, INC. | $280.31 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $253.36 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $218.76 | 2019-2021 | |
| Corium, LLC | $203.94 | 2022-2025 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.81 | 2019-2024 | Xifaxan |
| Abbott Laboratories | $199.67 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.